Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Here's some of what is coming soon to NeurologyLive® this week.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy
2
Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease
3
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
4
MDS Congress 2026: Late-Breaking Data Snapshot
5